ATXI stock icon

Avenue Therapeutics
ATXI

$3.71
9.12%
 

About: Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.

Employees: 3

0
Funds holding %
of 6,689 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

222% more capital invested

Capital invested by funds: $52.4K [Q4 2023] → $169K (+$116K) [Q1 2024]

0.15% more ownership

Funds ownership: 2.45% [Q4 2023] → 2.6% (+0.15%) [Q1 2024]

7% less funds holding

Funds holding: 15 [Q4 2023] → 14 (-1) [Q1 2024]

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Research analyst outlook

We haven’t received any recent analyst ratings for ATXI.

Financial journalist opinion

Neutral
GlobeNewsWire
1 month ago
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 689,680 shares of the Company's common stock. The exercised warrants are comprised of warrants to purchase shares of common stock originally issued by Avenue on October 11, 2022, each having an exercise price of $116.25 per share, Series A and Series B warrants to purchase shares of common stock originally issued by Avenue on November 2, 2023, each having an exercise price of $22.545 per share, and warrants to purchase shares of common stock originally issued by Avenue on January 9, 2024, each having an exercise price of $22.545 per share. The warrant holders agreed to exercise these warrants for cash at a reduced exercise price of $6.20 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 (File Nos. 333-267206 and 333-274562) and Form S-3 (No. 333-276671). The gross proceeds to Avenue from the exercise of the warrants are expected to be approximately $4.4 million, prior to deducting placement agent fees and offering expenses. The closing of the warrant exercise transaction is expected to occur on or about May 1, 2024, subject to satisfaction of customary closing conditions.
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds